Carbonic Anhydrase Inhibitors Clinical Trials

All Categories Medications / Interventions » Cc » Carbonic Anhydrase Inhibitors

Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Latin America

Condition: Glaucoma
Intervention: Drug: Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)
Sponsors: Alcon Research; Alcon Research
Recruiting - verified January 2012
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brinomidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil

Condition: Glaucoma
Intervention: Drug: Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)
Sponsors: Alcon Research; Alcon Research
Recruiting - verified March 2012
AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure

Condition: Glaucoma
Intervention: Drug: Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)
Sponsors: Alcon Research; Alcon Research
Recruiting - verified December 2011
Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada

Condition: Glaucoma
Intervention: Drug: Brinzolamide 1% / timolol 0.5% maleate fixed combination (AZARGA®)
Sponsors: Alcon Research; Alcon Research
Recruiting - verified January 2012
Predicting Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients

Condition: Heart Failure
Interventions: Drug: Acetazolamide; Drug: Placebo
Sponsors: Brigham and Women's Hospital; Atul Malhotra, MD; American Heart Association
Recruiting - verified August 2011
Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-angle Glaucoma or Ocular Hypertension

Conditions: Open-angle Glaucoma; Ocular Hypertension
Interventions: Drug: Brinzolamide 1% +Timolol 0.5% fixed combination; Drug: Brinzolamide 1% and Timolol 0.5%
Sponsors: Alcon Research; Alcon Research
Recruiting - verified November 2011
Patient Preference Comparison of AZARGA Versus COSOPT

Condition: Glaucoma
Interventions: Drug: Brinzolamide/Timolol Maleate Fixed Combination (Azarga); Drug: Dorzolamide/Timolol Maleate Fixed Combination (Cosopt)
Sponsors: Alcon Research; Alcon Research
Recruiting - verified November 2011
Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

Conditions: Open-angle Glaucoma; Ocular Hypertension
Interventions: Drug: Brinzolamide 1% / brimonidine 0.2% ophthalmic suspension; Drug: Brinzolamide 1% Eye drops, suspension BID (AZOPT); Drug: Brimonidine Tartrate
Sponsors: Alcon Research; Alcon Research
Recruiting - verified November 2011
Efficacy and Safety of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination BID vs. Brinzolamide 1% BID Plus Brimonidine 0.2% BID

Condition: Open-angle Glaucoma or Ocular Hypertension
Interventions: Drug: Brinzolamide 1% / brimonidine 0.2% ophthalmic suspension; Other: Vehicle for masking purposes; Drug: Brinzolamide 1% ophthalmic suspension (AZOPT); Drug: Brimonidine 0.2% ophthalmic solution
Sponsors: Alcon Research; Alcon Research
Recruiting - verified November 2011
Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome

Condition: Infantile Nystagmus Syndrome
Interventions: Drug: topical brinzolamide 1% in 5mL ophthalmic medication; Drug: Placebo in 5 mL dispenser
Sponsors: Akron Children's Hospital; Akron Children's Hospital
Recruiting - verified December 2011
Safety and Efficacy of Adding Azarga Adjunctive to Prostaglandin Therapy

Condition: Glaucoma
Intervention: Drug: Brinzolamide/Timolol Maleate Fixed Combination (Azarga)
Sponsors: Alcon Research; Alcon Research
Recruiting - verified November 2011
Idiopathic Intracranial Hypertension Treatment Trial

Condition: Idiopathic Intracranial Hypertension
Interventions: Drug: Acetazolamide; Drug: Placebo; Behavioral: Formal weight loss counselling program
Sponsors: St. Luke's-Roosevelt Hospital Center; St. Luke's-Roosevelt Hospital Center; National Eye Institute (NEI); University of Rochester; University of Iowa; University of California, Davis
Recruiting - verified May 2012
Treatment of Orthostatic Intolerance

Conditions: Tachycardia; Chronic Orthostatic Intolerance
Interventions: Drug: Acetazolamide; Drug: Atomoxetine; Other: Baseline (No Drug); Drug: Clonidine; Drug: Entacapone; Drug: Entacapone & Propranolol; Drug: Atomoxetine & Propranolol; Drug: Indomethacin; Drug: Mecamylamine; Drug: Isosorbide Dinitrate; Dietary Supplement: Melatonin; Drug: Midodrine; Drug: Modafinil; Drug: Octreotide; Radiation: Placebo; Drug: Propranolol; Drug: Modafinil & Propranolol; Drug: Sertraline; Procedure: IV Saline; Other: Drinking Water; Device: Breathing Device; Drug: memantine; Device: Abdominal binder
Sponsors: Vanderbilt University; Satish R. Raj; National Institutes of Health (NIH)
Recruiting - verified February 2012
Treatment of Orthostatic Hypotension in Autonomic Failure

Conditions: Autonomic Failure; Orthostatic Hypotension
Interventions: Drug: Atomoxetine; Drug: Acarbose; Drug: Pyridostigmine Bromide; Drug: Yohimbine; Drug: Midodrine HCl; Drug: placebo; Drug: Modafinil; Drug: Octreotide; Other: water intake; Drug: Diphenhydramine Hydrochloride; Drug: Ranitidine HCL; Drug: Tranylcypromine; Drug: Ergotamine/ Caffeine; Drug: Celecoxib; Drug: Pseudoephedrine; Drug: Methylphenidate; Drug: Indomethacin; Drug: Ibuprofen; Drug: Oxymetazoline 0.05% nasal solution; Dietary Supplement: Bovril; Drug: Acetazolamide; Drug: Rivastigmine tartrate; Drug: Carbidopa/levodopa; Device: abdominal binder; Device: abdominal binder (sham)
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012